SR7826 是一类由双芳基脲衍生的有效,选择性和具有口服活性的 LIM 激酶 (LIMK) 抑制剂,对于LIMK1的IC50为 43 nM。SR7826 对LIMK1的选择性比 ROCK 和 JNK 激酶高 100 倍以上。
生物活性 | SR7826 is a class of bis-aryl urea derived potent, selective and orally activeLIM kinase (LIMK)inhibitor with anIC50of 43 nM forLIMK1. SR7826 is >100-fold more selective forLIMK1thanROCKandJNKkinases[1]. |
IC50& Target | LIMK1 43 nM (IC50) | ROCKI 5536 nM (IC50) | ROCKII 6565 nM (IC50) |
|
体外研究 (In Vitro) | In the profiling against a panel of 61 kinases, SR7826 (compound 18b) at 1 μM inhibits only Limk1 and STK16 with ≥80% inhibition. SR7826 is highly efficient in inhibiting cell-invasion/migration in PC-3 cells. SR7826 (compound 18b) inhibits cofilin phosphorylation in A7r5 (IC50= 470 nM) and PC-3 cells (IC50< 1 μM)[1]. SR7826 (1 μM) inhibits contractions of prostate strips, which were induced by electrical field stimulation and inhibits cofilin phosphorylation in prostate tissues and cultured stromal cells (WPMY-1). In WPMY-1 cells, SR7826 causes breakdown of actin filaments and reduced viability[3].
|
体内研究 (In Vivo) | SR7826 (10 mg/kg; oral gavage; once daily; for 11 days; hAPPJ20 mice) treatment significantly reduces the phosphorylation of cofilin at Ser3. SR7826 also increases both apical and basal thin spine density significantly in hAPPJ20 mice over mock-treated animals[2]. The plasma pharmacokinetics studies on rats are investigated. After intravenous injection, the PK properties of SR7826 (compound 18b; 1mg/kg) with a Cl of 5.2 mL/min/kg, a T1/2of 2.2h, an AUC of 8.4 μM*h and a Cmaxof 7.7 μM, and has 36% oral bioavailability in rats (oral administration; 2mg/kg)[1].
Animal Model: | hAPPJ20 mice (6-mouth-old)[2] | Dosage: | 10 mg/kg | Administration: | Oral gavage; once daily; for 11 days | Result: | Significantly reduced the phosphorylation of cofilin at Ser3, a LIMK1 substrate. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(258.11 mM;Need ultrasonic) 配制储备液 1 mM | 2.5811 mL | 12.9056 mL | 25.8111 mL | 5 mM | 0.5162 mL | 2.5811 mL | 5.1622 mL | 10 mM | 0.2581 mL | 1.2906 mL | 2.5811 mL |
*请根据半岛bd体育手机客户端
在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端
失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (6.45 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (6.45 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.45 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。
*以上所有助溶剂都可在本网站选购。 |